TN-ARIES-CLEAN-TECH
19.11.2021 17:49:06 CET | Business Wire | Press release
Aries has reached another major milestone, achieving mechanical completion of the Aries Linden Biosolids Gasification Plant in Linden, New Jersey. This fluidized bed gasification plant is currently the largest facility of its type in the world. Commissioning is underway and is expected to be completed over the next few months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211119005608/en/
At full capacity, the plant will process 430 tons of biosolids daily (130,000 tons per year) diverting it from local landfills. This will also result in the production of approximately 22 tons per day of beneficial Bio-Fly-Ash™, a renewable product that will be sold as an additive to local concrete companies. The plant is located in a re-purposed building within the Linden Roselle Sewerage Authority (LRSA) complex.
“A special congratulations to Renus Kelfkens, Aries Executive Vice President - Engineering and all the Aries Clean Technologies team on this major milestone,” said Gregory Bafalis , CEO of Aries. “These teams have worked thousands of hours and delivered all fabrication and installation within two years from groundbreaking. I have no doubt this technology will become a new standard for the safe conversion of biosolids into beneficial use products.
“Currently 90% of the domestic Class A biosolids market is disposed of through ineffective conventional means such as landfilling, land application, or incineration. The fluidized bed technology can safely and efficiently stop this now and generate clean energy and Bio-Fly-Ash™,” Bafalis added.
“We’ve looked forward to celebrating this historic date that brings new technology and progress towards a cleaner environment to Linden and the Garden State,” said Derek Armstead , Mayor of Linden. “The Aries Build-Own-Operate model provides no financial risk to the LRSA or to the City of Linden but brings with it new, high-paying, green jobs in the clean tech industry for the people of Linden. And I’m so pleased that 16 new, permanent positions will bring this plant to life. We look forward to a long partnership with the Aries Linden team.”
Even before construction began, collaborations were underway with LRSA and the State of New Jersey Department of Environmental Protection (NJDEP). The awarding of the environmental permits not only validates Aries biosolids solutions but helps bring the state closer to its environmental goals. Permits addressed areas such as site use, soil conservation, air quality, water usage, and electrical generation and consumption.
Financing was provided in part through the sale of $61.5 million of “Green” tax-exempt bonds issued through the Union County Improvement Authority. Equity for the project comes principally from Aries Clean Technologies and Spring Lane Capital . “This project and Aries’ gasification technology fit perfectly with Spring Lane’s investment approach of partnering with leaders in the energy, water, food, and waste industries to help them deploy innovative, sustainable solutions. We are thrilled to support the Aries team on this and future projects,” said Nikhil Garg, General Partner at Spring Lane Capital.
Current research indicates that the fluidized bed gasification process will become an efficient method to address and destroy the quickly growing problem of per- and polyfluoroalkyl substances (PFAS). These man-made chemicals are used in many industrial applications and are very pervasive in the environment and human body. PFAS accumulates over time, leading to adverse health effects. Current studies show that the high temperature reached during the gasification process destroys any PFAS in biosolids as well as other bacteria, viruses, mold, fungus, etc.
The closed-loop system runs primarily on clean sustainable, renewable synthetic gas rather than relying on fossil fuels during operations. It is carbon negative and captures methane (with a global warming impact 23 times greater than CO2) that would otherwise be released into the atmosphere through the decomposition of biosolids. Greenhouse gases will also be reduced due to the reduction in trucking miles to reach existing, conventional disposal methods.
LRSA, created in 1948, services the City of Linden and the Borough of Roselle. It was established to contract and operate wastewater treatment and interceptor facilities to collect, treat, and dispose of sewage generated by the municipalities.
In addition to being the lowest cost option for biosolids disposal in the Linden area, the plant will serve the largest metropolitan area in the U.S., New York, that includes New York City, Long Island, and the Mid and Lower Hudson Valley in the state of New York and five of the largest cities in New Jersey: Newark, Jersey City, Paterson, Elizabeth, and Edison, and their vicinities.
About Aries Clean Technologies
Aries Clean Technologies, based in Franklin, Tennessee, develops, designs, and builds innovative proprietary fluidized bed and downdraft gasification systems and projects using its eight patents granted to date. Its projects provide for the sustainable conversion of biosolids and biomass, reduction of carbon emissions, and the production of clean thermal and electrical energy and beneficial Aries GREEN ® Biochar or Bio-Fly-Ash™. For more information, please visit our website: www.ariescleantech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005608/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom